Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report

• Published in: Prostate cancer and prostatic diseases Vol. 9; no. 2; pp. 195 - 197
• Main Authors: Tseng, T Y, Sevilla, D W, Moul, J W, Maloney, K E
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01-06-2006
• Subjects: Adenocarcinoma; Adenocarcinoma - pathology; Adenocarcinoma - radiotherapy; Aged; Biopsy, Needle; Brachytherapy; Brachytherapy - methods; Cancer; Carcinosarcoma - pathology; Carcinosarcoma - surgery; Case reports; Combined Modality Therapy; Follow-Up Studies; Humans; Immunohistochemistry; Iridium Radioisotopes - therapeutic use; Male; Neoplasm Recurrence, Local - pathology; Neoplasm Recurrence, Local - surgery; Neoplasm Staging; Neoplasms, Multiple Primary - pathology; Neoplasms, Multiple Primary - surgery; Neoplasms, Radiation-Induced - pathology; Neoplasms, Radiation-Induced - surgery; Pelvic Exenteration; Prostate cancer; Prostate-Specific Antigen - blood; Prostatic Neoplasms - pathology; Prostatic Neoplasms - radiotherapy; Radiation; Radiation dosage; Radiation therapy; Rectal Neoplasms - pathology; Rectal Neoplasms - surgery; Sarcoma; Time Factors; Treatment Outcome
• ISSN: 1365-7852; 1476-5608
• DOI: 10.1038/sj.pcan.4500870

A 65-year-old man with a history of combined pelvic external beam radiation therapy (EBRT) and brachytherapy for prostatic adenocarcinoma 15 years prior underwent total pelvic exenteration for presumed rectal sarcoma with prostatic invasion. Pathology revealed carcinosarcoma of prostatic origin. This patient exhibited the longest reported interval between initial presentation with prostatic adenocarcinoma and development of carcinosarcoma. This case is also the first reported case of prostatic carcinosarcoma occurring after combined EBRT and brachytherapy. The increasing use of such combination high-dose radiation therapy may potentially lead to an increased incidence of secondary malignancies such as prostatic carcinosarcoma in the future.